Stereotactic Ablative Radiosurgery for Locally Advanced or Recurrent Skull Base Malignancies with Prior External Beam Radiation Therapy by Karen M. Xu et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 17 March 2015
doi: 10.3389/fonc.2015.00065
Stereotactic ablative radiosurgery for locally advanced or
recurrent skull base malignancies with prior external beam
radiation therapy
Karen M. Xu1, Kimmen Quan1, David A. Clump1, Robert L. Ferris1,2 and Dwight E. Heron1,2*
1 Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
2 Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Edited by:
Christina Tsien,Washington
University, USA
Reviewed by:
James ByunghoonYu, Yale School of
Medicine, USA
Samuel Chao, Cleveland Clinic, USA
*Correspondence:
Dwight E. Heron, Department of
Radiation Oncology, University of
Pittsburgh Cancer Institute, 5230
Centre Avenue, Pittsburgh, PA 15232,
USA
e-mail: herond2@upmc.edu
Purpose: Stereotactic ablative radiotherapy (SABR) is an attractive modality to treat malig-
nancies invading the skull base as it can deliver a highly conformal dose with minimal
toxicity. However, variation exists in the prescribed dose and fractionation. The purpose of
our study is to examine the local control, survival, and toxicities in SABR for the treatment
of previously irradiated malignant skull base tumors.
Materials and methods: A total of 31 patients and 40 locally advanced or recurrent head
and neck malignancies involving the skull base treated with a common SABR regimen,
which delivers a radiation dose of 44 Gy in 5 fractions from January 1st, 2004 to Decem-
ber 31st, 2013, were retrospectively reviewed.The local control rate (LC), progression-free
survival rate, overall survival (OS) rate, and toxicities were reported.
Results: The median follow-up time of all patients was 11.4 months (range: 0.6–
67.2 months). The median tumor volume was 27 cm3 (range: 2.4–205 cm3). All patients
received prior external beam radiation therapy with a median radiation dose of 64 Gy (range:
24–75.6 Gy) delivered in 12–42 fractions. Twenty patients had surgeries prior to SABR.
Nineteen patients received chemotherapy. Specifically, eight patients received concurrent
cetuximab (Erbitux™) with SABR. The median time-to-progression (TTP) was 3.3 months
(range: 0–16.9 months). For the 29 patients (93.5%) who died, the median time from the
end of first SABR to death was 10.3 months (range: 0.5–41.4 months).The estimated 1-year
OS rate was 35%. The estimated 2-year OS rate was 12%. Treatment was well-tolerated
without grade 4 or 5 treatment-related toxicities.
Conclusion: Stereotactic ablative radiotherapy has been shown to achieve low toxicities
in locally advanced or recurrent, previously irradiated head and neck malignancies invading
the skull base.
Keywords: SABR, low toxicities, re-irradiation, skull base malignancies, high-dose
INTRODUCTION
Skull base tumors (SBT) may originate from various tissues of
the skull base or from direct extensions of head and neck cancers
(1). The skull base is also a common site of metastasis from dis-
tant tumors (2, 3). Common clinical presentations include pain
and cranial nerve deficits, such as visual disturbances, facial pare-
sis, dysphagia, and odynophagia, which bring great suffering to
the patients (4). However, due to their close proximity to critical
neurovascular structures, treatment of malignant tumors involv-
ing the skull base presents a difficult challenge to the clinician,
especially when such tumors persist or recur after surgery and/or
external beam radiation therapy (EBRT) (5).
Recently, fractionated stereotactic radiotherapy has become an
attractive modality to re-irradiate skull base malignancies since it
can deliver a highly conformal dose to the tumor while minimiz-
ing radiation to surrounding critical structures (6–9). However,
there is no consensus on the stereotactic dose and fractionation.
In this study, we report our institution’s experience using linear
accelerator-based stereotactic ablative radiotherapy (SABR) for the
treatment of locally advanced or recurrent skull base malignancies.
MATERIALS AND METHODS
PATIENT POPULATION
With approval from our institutional review board (IRB), we
performed a retrospective review of 31 patients with 40 locally
advanced or recurrent, previously irradiated skull base malig-
nancies treated with high-dose fractionated SABR at our insti-
tution from January 1, 2004 to December 31, 2013 with Eastern
Cooperative Oncology Group (ECOG) performance status of 0–2.
SIMULATION AND PLANNING
Each patient received pretreatment skull based MRI or 18F-
fluorodeoxy-glucose (18F-FDG) PET/CT scans, which were fused
with contiguous ≤2.5-mm-thick slice CT treatment planning
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images using commercially available fusion software. Our methods
for the use of 8F-FDG PET/CT scans in head and neck cancers were
described previously (10). Patients were placed in a supine posi-
tion in an alpha cradle both during CT imaging and the treatment
and immobilized with a rigid thermoplastic Aquaplast™ facemask
(WRF/Aquaplast Corp., Wyckoff, NJ, USA). The tumor volume
and surrounding critical structures were contoured by a radiation
oncologist and a head and neck surgeon. Quality assurance testing
of the treatment plan was based on phantom dose measurements
by a radiation physicist. An ideal SABR treatment plan provided
coverage of 95% of the prescription dose to the PTV while sparing
surrounding critical organs such as the left and right eye, left and
right optic nerve, chiasm, brainstem, and spinal cord.
STEREOTACTIC RADIOTHERAPY DELIVERY SYSTEMS
Three platforms were used: Cyberknife™, Varian Trilogy™, and
Truebeam™ STX (11). Cyberknife™ uses a compact 6-MV lin-
ear accelerator mounted on a computer-controlled robotic arm
with six rotation axes that permit the use of 1200 treatment posi-
tions, of which 80–120 are usually necessary to treat most lesions.
Throughout the treatment delivery, two orthogonally positioned
diagnostic x-ray cameras provide images of the patient’s anatomy.
Bony landmarks or implanted fiducial markers were used to com-
pare the patient’s planning CT to allow for continuous adjustment
(intra-fraction correction) based on the patient’s positioning (12).
For Varian Trilogy™ and Truebeam™ STX, a cone-beam CT was
acquired and pre-treatment shifts were made to match the plan-
ning scan after immobilization of the patient and isocentric set-up.
Via beam modulation and occasionally using RapidArc™ technol-
ogy, dose is delivered both efficiently and conformally (13, 14).
For the 40 locally advanced or recurrent malignant skull base
tumors (SBT) in our study, 26 were treated with Cyberknife™,
8 were treated with Varian Trilogy™, and 6 were treated with
Truebeam™ STX.
CLINICAL ASSESSMENT AND FOLLOW-UP
Follow-up typically began 1 month after the completion of SABR.
Patients were subsequently followed in 3- to 4-month intervals
afterwards. During each follow-up visit, a clinical evaluation and
physical examination were performed. MRI or PET-CT imaging
studies were also obtained to assess any changes in tumor size or
to identify the development of any new lesions. The follow-up
duration was calculated from the end of SABR to the most recent
follow-up time or in most cases, the cease to breathe date.
DATA ANALYSIS
Tumor response to the treatment was graded using the Response
Evaluation Criteria in Solid Tumors (RECIST) criteria. Local fail-
ure (LF) was defined as any progression of disease in the target
volume of the SABR. Regional failure (RF) was defined as any
progression of disease in regional lymph nodes. Distant failure
(DF) was defined as any progression of disease outside the target
volume of the SABR, and not RF. Progression-free survival (PFS)
was defined as any progression (local, regional, or distant) from
the completion date of SABR. Overall survival (OS) defined as the
time from the completion of the first SABR to the date of death.
Survival curves and median survival time were estimated using
the Kaplan–Meier method. All statistical tests were run using SPSS
Version 22.0 (SPSS, Chicago, IL, USA) with a p value<0.05 consid-
ered statistically significant. Acute (<90 days) and late (>90 days)
toxicities were assessed at follow-up visits approximately every
3 months after the treatment was complete. At each visit, toxici-
ties were recorded based on the National Cancer Institute (NCI)
Common Terminology Criteria for Adverse Events (CTCAE) Ver-
sion 4.0. For this study, we gathered toxicity data retrospectively
through patient chart review.
RESULTS
PATIENT CHARACTERISTICS
Between January 2004 and December 2013, 31 patients with 40
locally advanced or recurrent, previously irradiated skull base
malignancies were treated with SABR. The median age of the
patients was 58.6 years old (range: 32.3–87.4 years old). Eighteen
patients were males and 13 were females. The median follow-up
time of all patients was 11.4 months (range: 0.6–67.2 months).
Except two patients, all (n= 29) had a follow-up duration of
more than 90 days. The median tumor volume was 27 cm3 (range:
2.4–205 cm3). Primary locations of tumors included oropharynx,
nasopharynx, maxillary sinus, parotid gland, base of skull, sali-
vary gland, tonsil, thyroid, retromolar trigone, ear canal, paranasal
sinus, base of tongue, adenoid, and head and neck. Histology of
tumors included squamous cell carcinoma, adenoid cystic carci-
noma, adenocarcinoma, olfactory neuroblastoma, small cell carci-
noma, medullary carcinoma, malignant fibrous histiocytoma, and
the undifferentiated. The results were summarized in Table 1.
TREATMENT REGIMEN
All patients received prior EBRT with a median radiation
dose of 64 Gy (range: 24–75.6 Gy) delivered in 12–42 fractions.
Twenty patients received prior surgery. Nineteen patients received
chemotherapy, either chemotherapy prior to SABR or concurrent
chemoradiation. Specifically, eight patients received concurrent
cetuximab (Erbitux™) with SABR. The biologically effective dose
(assuming an alpha/beta ratio of 10, for acute responding tis-
sues or tumor effects), BED10, received by patients before SABR,
was calculated for each patient according to the formula BED10
(Gy)= total dose× [1+ (Dose per fraction)/10]. The median
BED10 was 82.7 Gy (range: 22.5–100 Gy). The biologically effec-
tive dose (assuming an alpha/beta ratio of 3, for late responding
tissues or normal organ effects), BED3, received by patients before
SABR, was calculated for each patient according to the formula
BED3 (Gy)=Total dose× [1+ (dose per fraction)/3]. The median
BED3 was 173.1 Gy (range: 40–216.7 Gy). The homogeneity index
(HI) was calculated for each treatment plan. The HI describes the
uniformity of dose within a treated target volume and is calculated
according to the formula HI=maximum dose/prescription dose.
The median HI was 1.3 (range: 1.1–1.3). The median SABR dose
was 44 Gy (range: 15–50 Gy) and was delivered at a median isodose
line of 80% (range: 75–94%) in one to five fractions. The median
treatment duration was 10.5 days (range: 1–34 days). All patients
completed the treatment course without toxicity-related breaks.
TREATMENT RESPONSE, TUMOR CONTROL, AND SURVIVAL
Out of the 40 locally advanced or recurrent skull base malignant
tumors treated with SABR, 3 (7.5%) had complete response (CR);
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Table 1 | Patient characteristics.
Characteristics No. (%)
Age (years)
Median 58.6
Range 32.3–87.4
Gender
Male 18 (58)
Female 13 (42)
Follow-up (months)
Median 11.4
Range 0.6–67.2
Tumor volume (cc)
Median 27
Range 2.4–205
Primary sites
Oropharynx 3 (9.7)
Nasopharynx 7 (22.6)
Maxillary sinus 3 (9.7)
Parotid gland 3 (9.7)
Base of skull 3 (9.7)
Salivary gland 1 (3.2)
Tonsil 3 (9.7)
Thyroid 1 (3.2)
Retromolar trigone 1 (3.2)
Ear canal 1 (3.2)
Paranasal sinus 1 (3.2)
Base of tongue 2 (6.5)
Adenoid 1 (3.2)
Head and neck 1 (3.2)
Histology
Squamous cell carcinoma 17 (54.8)
Adenoid cystic carcinoma 6 (19.4)
Adenocarcinoma 1 (3.2)
Olfactory neuroblastoma 1 (3.2)
Small cell carcinoma 1 (3.2)
Medullary carcinoma 1 (3.2)
Malignant fibrous histiocytoma 1 (3.2)
Undifferentiated 2 (6.5)
Unknown 1 (3.2)
7 (17.5%) had partial response (PR); 12 (30%) had stable disease
(SD); and 9 (22.5%) had progressive disease (PD). The treatment
responses for nine (22.5%) tumors were unknown mostly because
the post-treatment imaging was unavailable.
The median follow-up time for all 31 patients was 11.4 months
(range: 0.6–67.2 months). At the most recent follow-up, or at the
time of death, 20 out of 40 (50%) SABR treatments had LF only.
Six treatments (15%) had both local and DF; one (2.5%) treat-
ment had both regional and DF; three (7.5%) treatments had local,
regional, and DF. Three (7.5%) treatments were completely free of
any local, regional, or DF. The outcomes for 7 (17.5%) treatments
were unknown due to lack of follow-up imaging. All patients, who
died, developed LF. For those patients with distant metastasis, six
metastasized to the lungs only (60%); one metastasized to the
tracheoesophageal groove (10%); one metastasized to the hilar
FIGURE 1 | Survival curves. PFS, progression-free survival; OS, overall
survival.
lymph nodes (10%); one metastasized to the subcarinal lymph
nodes (10%); and one metastasized to both the lung and the
periesophageal lymph nodes (10%). One patient with small cell
carcinoma in the head and neck did not develop local, regional,
or DF after the SABR, but died from multiple myeloma. For the
other two patients free of local, regional, or DF, one had adenoid
cystic carcinoma in the parotid and is still alive and the other had
T3 N1 M0 medullary carcinoma in the thyroid and is also alive.
The median time-to-progression (TTP) was 3.3 months (range:
0–16.9 months). The estimated 3-month PFS, 6-month PFS, 9-
month PFS were 55, 26, and 15%, respectively. Two patients (6.5%)
were alive at the end of the follow-up period. For the 29 patients
(93.5%) who died, the median time from the completion of first
SABR to death was 10.3 months (range: 0.5–41.4 months). The
estimated 1-year OS rate was 35%. The estimated 2-year OS rate
was 12%. Both the PFS curve and the OS curve were shown in
Figure 1.
DOSIMETRIC PARAMETERS
The median maximum radiation dose to the tumor was 51.3 Gy
(range: 22.2–58.7 Gy). In addition, we measured the irradiated
volume and the radiation dose to critical surrounding structures
including the left and the right eye, left and right optic nerve,
the chiasm, the brainstem, and the spinal cord. The detailed
information was summarized in Table 2.
TOXICITY ASSESSMENT
Treatment was well-tolerated without any grade 4 or 5 treatment-
related toxicities. All toxicities were listed in Table 3. Only 6 out
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Table 2 | Dosimetric parameters for surrounding critical structures.
Tissue Volume (cm3),
median (range)
Maximum radiation dose
(Gy), median (range)
Left eye 9.1 (1.8− 12.6) 1.5 (0− 40.5)
Right eye 8.7 (5.7− 13.8) 3.05 (0− 28)
Left optic nerve 0.94 (0.4− 1.5) 9.9 (0.72− 47.5)
Right optic nerve 1.1 (0.4− 2) 7 (0.93− 48.5)
Chiasm 0.8 (0.3− 4.7) 5.5 (0.5− 43.4)
Brainstem 25 (6.6− 57.2) 14.7 (1.05− 39.9)
Spinal cord 25.9 (1.75−62.7) 7.8 (0.97− 33.7)
of 40 (15%) SABR treatments led to significant toxicities (1 with
acute grade 3 Erbitux associated rash, 1 with acute grade 3 alopecia,
1 with acute grade 3 dysgeusia, 1 with acute grade 3 hyperpigmen-
tation1, 1 with late grade 3 headache, and 1 with late grade 3
trismus).
DISCUSSION
Locally advanced or recurrent skull base malignancies have a very
poor prognosis and are frequently inoperable due to the risk
of severe brainstem and cranial nerve morbidities (15, 16). Re-
irradiation of these patients is also clinically challenging due to the
tumor’s proximity to critical neurovascular structures. Recently,
fractionated stereotactic radiotherapy has become an attractive
option to re-treat skull base malignancies, but there is no consen-
sus on the optimal dose and fractionation for SABR as it applies
to skull base malignancies. SABR is uniquely suitable for treat-
ing skull base malignancies as it is non-invasive and can target
the tumor with great precision and conformity. However, there is
very limited literature on the utilization of SABR for re-irradiating
malignant SBT. To our knowledge, our study is the first to report
toxicities of SABR for treating locally advanced or recurrent skull
base malignancies with prior EBRT.
Cmelak et al. (17) reported a study of 47 patients with 59
malignant SBT. Among these patients, 37 were treated for 48 skull
base metastases or local recurrences from primary head and neck
cancers without previous irradiation. Eleven were treated for pri-
mary nasopharyngeal carcinoma using radiotherapy as a boost
after a course of fractionated radiotherapy (64.8–70 Gy) with-
out chemotherapy. The median tumor size was 8 cm3 (range:
0–51 cm3). A median radiation dose of 20 Gy (range: 7–35 Gy)
was typically delivered in a single fraction. The median follow-up
time was 9 months (range: 1–60 months). The crude local control
rate (LC) was 33/48 (69%) during the follow-up period. Survival
was not reported. Major complications developed in 5 out of 59
treatments, including three cranial nerve palsies, one CSF leak, and
one trismus of unknown grade.
Miller et al. (18) reported a study of 32 patients with 35 newly
diagnosed or recurrent malignant SBT treated with the Leksell
Gamma unit. The median tumor size was 14.6 cm3 (range: 2.9–
52.1 cm3). The median radiation dose was 15 Gy (range: 12–20 Gy)
delivered in a single fraction. Three-year LC was 78% and 3-year
OS rate was 72%. One patient received retreatment with hyper-
fractionated EBRT of 31.2 Gy about 1.7 years after the radiother-
apy. Two patients with recurrent adenoid cystic carcinomas were
Table 3 |Toxicities after treatment.
Adverse event Acute (<90days)
(n=29)
Late (>90days)
(n=5)
Erbitux™ associated rash
Grade 1 2 (6.9%)
Grade 2 2 (6.9%)
Grade 3 1 (3.4%)
Nausea
Grade 2 2(6.9%)
Trismus
Grade 3 1 (20%)
Alopecia
Grade 3 1 (3.4%)
Pain
Grade 2 3 (60%)
Dysphagia
Grade 1 1 (3.4%)
Grade 2 1 (3.4%)
Xerostomia
Grade 1 2 (6.9%)
Grade 2 1 (3.4%)
Mucositis
Grade 1 2 (6.9%)
Grade 2 4 (13.8%)
Dysgeusia
Grade 1 2 (6.9%)
Grade 3 1 (3.4%)
Telangiectasia
Grade 1 1 (3.4%)
Skin atrophy
Grade 2 1 (3.4%)
Headache
Grade 2 1 (3.4%)
Grade 3 1 (20%)
Odynophagia
Grade 1 1 (3.4%)
Epistaxis
Grade 1 1 (3.4%)
Hyperpigmentation
Grade 3 1 (3.4%)
previously treated with EBRT. One patient developed a radiation-
induced optic neuropathy 12 months after radiotherapy. Majority
of the patients had adenoid cystic carcinoma or chordoma.
Coppa et al. (5) reported a study of 31 patients with malig-
nant SBTs. None of the patients were previously irradiated. The
median follow-up time was 8.5 months. Ten (32%) patients were
alive at the end of the follow-up period. The median OS was
8.6 months. For the 21 patients who died, the median time to death
was 5.75 months. The median radiation dose was 25 Gy (range:
12.6–35 Gy) delivered in a median number of five fractions (range:
2–7). No significant toxicity was reported. The studies mentioned
above were summarized in Table 4.
Though assessment of toxicity directly attributable to SABR
was difficult as most patients underwent multiple surgeries, EBRT
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Table 4 | Previous experiences of skull base malignancies treated by stereotactic radiotherapy.
Study Median tumor
size (cm3)
Techniques No. of
patients
Median f/u
(months)
Median total
dose (Gy)
Fractions OS LC
Cmelak et al. 8 (0− 51) Stereotactic radiotherapy 47 9 20 (7–35) 1 N/A 69%
Miller et al. 14.6 (2.9− 52.1) Gamma knife 32 27.6 15 (12–20) 1 3-year OS was 72% 78% at 3 years
Coppa et al. 18.3 (3.2−206.5) Cyberknife 31 8.5 25 (12.6–35) 5 (2–7) 5.75 74%
Our study 27 (2.4− 205) Cyberknife, TrueBeam,
Trilogy
31 11.4 44 (15–50) 5 (1–5) 10.3 3-month PFS
was 55%
f/u, follow-up; OS, overall survival; LC, local control.
treatments, and chemotherapy sessions, no grade 4 or 5 acute or
late radiation associated toxicities were noted in our study. There
were five grade 3 toxicities. This included acute grade 3 rash, alope-
cia, and dysgeusia and late grade 3 trismus and headache. On the
contrary, the single fraction radiotherapy studies reported rela-
tively high rates of significant toxicities. We believe that the lack of
significant toxicities is mostly due to delivering SABR in multiple
fractions with high conformity and homogeneity. Fractionation
and delivery of radiation every other day provide time for normal
tissues to repair themselves between doses and therefore mini-
mizes toxicities. Since our study is the first to report SABR for the
re-irradiation of skull base malignancies, all the cited literatures
were about using SABR for the treatment of locally advanced or
recurrent skull base malignancies without prior irradiation. How-
ever, single fraction SABR caused significant late toxicities even
in patients without prior irradiation, while multi-fraction SABR,
like in our study, did not cause any grade 4 or 5 late toxicities in
patients with prior EBRT. This shows that multi-fraction SABR
helped to decrease the likelihood of late toxicities.
In addition, the high conformity of SABR ensures that irradi-
ation to surrounding critical organs including left and right eye,
left and right optic nerve, the optic chiasm, the brainstem, and the
spinal cord was minimized as much as possible. In our study, the
median maximum radiation dose to the left eye and the right eye
was 1.5 and 3.05 Gy. The median maximum radiation dose to the
left and right optic nerve was 9.9 and 7 Gy. The median maximum
radiation dose to the optic chiasm was 5.5 Gy and the median max-
imum radiation dose to the brainstem was 14.7 Gy. The median
maximum radiation dose to the spinal cord was 7.8 Gy. Shown by
these dosimetric data, we can see that through its high conformity
and precision, SABR minimized the radiation dose to surround-
ing critical organs while delivering a high dose to SBT. This makes
SABR an attractive option for treating SBT becuase the biggest
challenge is to avoid injuring its surrounding critical neurovascular
structures.
Compared to previous studies, our study seems to have a rel-
atively low control rate. However, it is worth noting that all the
patients in our study have received previous EBRT. SABR was used
for retreatment of inoperable locally advanced or recurrent skull
base malignancies, not as a boost. Our median OS of 10.3 months
was superior to the previously reported study regarding locally
advanced or recurrent skull base malignancies as Coppa et al. only
had a median survival of 5.75 months. In addition, our study had
the largest tumor sizes among all the reported studies. The median
tumor size in our study was 27 cm3 with a range of 2.4 to 205 cm3.
Cmelak et al. had a median tumor size of 8 cm3; Miller et al had a
median tumor size of 14.6 cm3; Coppa et al. had a median tumor
size of 18.3 cm3. Furthermore, in our study, 17 patients (54.8%)
had squamous cell carcinoma and only 6 (19.4%) had adenoid
cystic carcinoma. Studies have shown that adenoid cystic carci-
noma has a better prognosis than squamous cell carcinoma (19). In
Miller et al., 12/32 (37.5%) patients had adenoid cystic carcinoma
and only 8/32 (25%) had squamous cell carcinoma. 8/32 (25%)
patients had chordoma, which is a rare, slow-growing malignant
tumor.
Our dose and fractionation of 44 Gy in five fractions seem to
be effective with acceptable long-term toxicities in this cohort of
patients. However, this needs to be validated through prospective
clinical trials. The dose ranges reported on Table 3 for critical
organs were quite broad, and may not represent what is clinically
appropriate. Currently, data are lacking regarding dose tolerances
to these structures, especially in the setting of re-irradiation.
CONCLUSION
Our study reported low toxicities with SABR for the re-irradiation
of locally advanced or recurrent skull base malignancies, most
likely due to the fractionation schedule and the high conformity
of SABR, which ensures that irradiation doses to surrounding
critical structures were minimized. Though fractionation seems
to minimize toxicities, there is no consensus regarding the dose
and fractionation of SABR for the treatment of skull base malig-
nancies. Coppa et al. (5) reported a median radiation dose of
25 Gy delivered in five fractions and hypothesized that a higher
average dose may still be associated with a low toxicity rate,
which is supported by our study. In conclusion, SABR with a
common regimen of 44 Gy delivered in five fractions has been
shown to minimize toxicities in the treatment of locally advanced
or recurrent skull base malignancies with prior EBRT at our
institution.
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